FDA Milestone: 75th Biosimilar Medication Is Approved!
U.S. Food and Drug Administration (FDA) shared on LinkedIn:
”Exciting Announcement!
The FDA has reached another milestone with the approval of its 75th biosimilar medication!
This achievement represents a major step forward in ensuring more patients have access to critical, life-saving treatments without compromising on quality or safety.
Learn more about biosimilars”
According to the FDA, a biosimilar is a biological product that closely resembles an already FDA-approved reference product and shows no clinically significant differences in safety or effectiveness.
Biosimilars are approved for use across a wide range of diseases, from Crohn’s disease to HER2-positive breast cancer.
For example, Zarxio can serve as an alternative to Neupogen (filgrastim), while the newly approved Avsola is intended to replace Remicade (infliximab) for various autoimmune conditions.
One key advantage of these drugs is that they maintain high standards of safety, efficacy, and quality, while also providing more cost-effective treatment options.
Thus, biosimilar products approved by FDA must also meet requirements mentioned in Biologics Price Competition and Innovation Act.

More on the latest FDA Approvals featured in Hemostasis Today.
-
Jan 8, 2026, 05:51Dominika Jędrzejewska Akbaş Links Sleep Deprivation, Obesity, and Stroke
-
Jan 8, 2026, 05:42Rob Maloney: A Bruise that Did Not Go Away…
-
Jan 8, 2026, 05:33Matías J Alet on Treating Early Neurological Deterioration in Lacunar Stroke
-
Jan 8, 2026, 05:11Thomas Meinel Shares The English Stroke Guidelines 2026
-
Jan 8, 2026, 05:03Hilla Ben-Pazi: We Were Pleased to Receive a Grant from the Israeli Ministry of Economy
-
Jan 8, 2026, 04:24Nikhil Agrawal Breaks Down Perioperative Anticoagulation
-
Jan 8, 2026, 03:58Louise St Germain Bannon Appointed Interim Executive Director of ISTH
-
Jan 8, 2026, 03:47Wolfgang Miesbach on Fernando Corrales-Medina’s Team’s Latest Cross-Sectional Study on Haemophilia
-
Jan 8, 2026, 03:28Rick Matthews: Powerful Perspective from Erin and the NBCA Team
